UNSPSC 51333405: Fenaperone

This classification denotes an anxiolytic with the molecular formula C21H29FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V6W7F1R86P, chemically known as 4-(3-(p-fluorobenzoyl)-propyl)-1-piperazinecarboxylic acid, cyclohexyl ester. but generally known as fenaperone, which bears US NIH Compound Identifier 198061. European Medicines Agency schedules Fenaperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07540MIG.

UNSPSC 51333405 Fenaperone is a Commodity code that does not reflect the pharmaceutical procurement activity currently being solicited by state and local governments. The recent opportunities posted under this code show that state and local buyers are actively purchasing naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter (OTC) products — none of which are fenaperone. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states and localities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mismatch between the code's nominal substance and the actual procurement scope suggests that fenaperone tagging may reflect administrative assignment rather than the goods and services state and local governments are sourcing under this code number.

The geographic spread of recent activity includes Florida, Texas, Minnesota, and Oregon through the MMCAP cooperative vehicle. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with responses due July 26, 2023. The Texas Health and Human Services Commission issued Request for Information HHS0017013 on April 3, 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about vendors' capacity for direct contracting outside traditional pharmacy benefit manager and wholesaler arrangements. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in participating states, with responses due March 26, 2026 and contract awards effective July 1, 2026. The code shows limited recent activity genuinely aligned with fenaperone procurement, making it difficult to characterize market concentration or issuing-body patterns with confidence.